Taken together, these findings imply that the cellular target for FXR-agonism to ultimately decrease hepatic fibrosis in our rat model of toxic cirrhosis is to be searched for further upstream in the cascade of HSC activation. This evidence concerns the gene NR1H4 and Cirrhosis.